Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer Intervention: Drug: Nivolumab Sponsors: Seoul National University Hospital; Seoul National University Bundang Hospital; Korean Cancer Study Group (KCSG); Eisai Korea; Ono pharmaceutical Korea Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials